203 related articles for article (PubMed ID: 30169978)
1. Clinical translation of immunoliposomes for cancer therapy: recent perspectives.
Wang D; Sun Y; Liu Y; Meng F; Lee RJ
Expert Opin Drug Deliv; 2018 Sep; 15(9):893-903. PubMed ID: 30169978
[TBL] [Abstract][Full Text] [Related]
2. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
3. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
5. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
[TBL] [Abstract][Full Text] [Related]
6. Future directions of liposome- and immunoliposome-based cancer therapeutics.
Park JW; Benz CC; Martin FJ
Semin Oncol; 2004 Dec; 31(6 Suppl 13):196-205. PubMed ID: 15717745
[TBL] [Abstract][Full Text] [Related]
7. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
Wang J; Wu Z; Pan G; Ni J; Xie F; Jiang B; Wei L; Gao J; Zhou W
Nanomedicine; 2018 Aug; 14(6):1949-1961. PubMed ID: 29045824
[TBL] [Abstract][Full Text] [Related]
8. Surface Ligand Valency and Immunoliposome Binding: when More Is Not Always Better.
Li H; Di J; Peng B; Xu Y; Zhang N
Pharm Res; 2021 Sep; 38(9):1593-1600. PubMed ID: 34463936
[TBL] [Abstract][Full Text] [Related]
9. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
10. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.
Xu L; Huang CC; Huang W; Tang WH; Rait A; Yin YZ; Cruz I; Xiang LM; Pirollo KF; Chang EH
Mol Cancer Ther; 2002 Mar; 1(5):337-46. PubMed ID: 12489850
[TBL] [Abstract][Full Text] [Related]
11. Anti-HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone-Fused Enediyne.
Feng X; Wen Z; Zhu X; Yan X; Duan Y; Huang Y
Adv Sci (Weinh); 2024 May; 11(17):e2307865. PubMed ID: 38355309
[TBL] [Abstract][Full Text] [Related]
12. Immunoliposomes for Targeted Delivery of an Antifibrotic Drug.
Schuster L; Seifert O; Vollmer S; Kontermann RE; Schlosshauer B; Hartmann H
Mol Pharm; 2015 Sep; 12(9):3146-57. PubMed ID: 26181293
[TBL] [Abstract][Full Text] [Related]
13. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
[TBL] [Abstract][Full Text] [Related]
14. Anti-HER2 immunoliposomes for targeted therapy of human tumors.
Park JW; Hong K; Kirpotin DB; Meyer O; Papahadjopoulos D; Benz CC
Cancer Lett; 1997 Oct; 118(2):153-60. PubMed ID: 9459205
[TBL] [Abstract][Full Text] [Related]
15. Antibody-labeled liposomes for CT imaging of atherosclerotic plaques: in vitro investigation of an anti-ICAM antibody-labeled liposome containing iohexol for molecular imaging of atherosclerotic plaques via computed tomography.
Danila D; Partha R; Elrod DB; Lackey M; Casscells SW; Conyers JL
Tex Heart Inst J; 2009; 36(5):393-403. PubMed ID: 19876414
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and
Hua S
J Liposome Res; 2019 Dec; 29(4):357-367. PubMed ID: 30526169
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
19. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles.
Santos EDS; Nogueira KAB; Fernandes LCC; Martins JRP; Reis AVF; Neto JBV; Júnior IJDS; Pessoa C; Petrilli R; Eloy JO
Int J Pharm; 2021 Jan; 592():120082. PubMed ID: 33188892
[TBL] [Abstract][Full Text] [Related]
20. PEG-immunoliposome.
Maruyama K
Biosci Rep; 2002 Apr; 22(2):251-66. PubMed ID: 12428903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
